2024-518285-27-00招募中4 期
A Phase I double blinded, single-center, randomized, crossover study comparing the PK, PD, safety and tolerability of a single IV dose (1µg/kg) of LB-0702 and Nplate® in healthy volunteers.
Laboratorio Reig Jofre S.A.1 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2025年3月18日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 34
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Mohammed Sharaf
Scientific
Laboratorio Reig Jofre S.A.
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years2023-506396-94-00Osivax48
已完成
1 期
PK and PD study of G-CSF (BioGenomics Ltd) vs Neupogen® in healthy volunteersCTRI/2017/10/010040BioGenomics Ltd59
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CH-4051 in healthy male subjects10003816rheumatoid arthritisNL-OMON32763Chelsea Therapeutics, Inc.56
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARA 290 Administered Intravenously to Healthy Subjects, and extension in renal patientsNL-OMON33878Araim Pharmaceuticals, Inc20
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Effect of tedalinab on ECG parameters, CNS Function and Pain Perception in Healthy Subjects.Chronic pain10034606NL-OMON34384Glenmark Pharmaceuticals80